Drug Profile

XTX 202

Alternative Names: XTX-202

Latest Information Update: 11 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Akriveia Therapeutics
Developer Xilio Therapeutics
Class Antineoplastics; Immunotherapies; Interleukins
Mechanism of Action Interleukin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Solid tumours

Most Recent Events

31 May 2024 Updated efficacy, pharmacokinetic and adverse event data from a phase I/II trial in Renal cell carcinoma and Melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
28 Mar 2024 Updated efficacy data from a phase I/II trial in Renal cell carcinoma and Melanoma released by Xilio Therapeutics
03 Nov 2023 XTX 202 is available for licensing as of 03 Nov 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com